Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
life sciences
zolgensma
8
×
gene therapy
national blog main
national top stories
novartis
boston blog main
clinical trials
national
new york top stories
san francisco top stories
boston top stories
new york blog main
san diego blog main
san diego top stories
san francisco blog main
biogen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
spinal muscular atrophy
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
avexis
bristol-myers squibb
deals
glaxosmithkline
startups
abbvie
What
roundup
bio
biotech
drug
news
therapy
fda
gene
healthcare
long
medicine
nash
new
public
remains
topped
access
according
advanced
akcea
america
approval
approved
atrophy
august
biogen
biogen’s
biopharmaceutical
busy
capacity
car
cases
cell
centers
cigarettes
companies
consolidation
continues
control
convo
Language
unset
Current search:
zolgensma
×
biotech
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More